Alpha 2.0
Login Register
» Articles » PMID: 2894566

Craniopharyngioma Recurrence and Growth Hormone Therapy

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1988 Mar 19
PMID 2894566
Citations 8
Authors
P E Clayton
D A Price
S M Shalet
H R Gattemaneni
Affiliations
Soon will be listed here.
Citing Articles

Predictive Factors for Pediatric Craniopharyngioma Recurrence: An Extensive Narrative Review.

Serbis A, Tsinopoulou V, Papadopoulou A, Kolanis S, Sakellari E, Margaritis K Diagnostics (Basel). 2023; 13(9).

PMID: 37174978 PMC: 10177772. DOI: 10.3390/diagnostics13091588.

A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma.

Clark A, Cage T, Aranda D, Parsa A, Sun P, Auguste K Childs Nerv Syst. 2012; 29(2):231-8.

PMID: 23089933 DOI: 10.1007/s00381-012-1926-2.

Long term sequelae of pediatric craniopharyngioma - literature review and 20 years of experience.

Cohen M, Guger S, Hamilton J Front Endocrinol (Lausanne). 2012; 2:81.

PMID: 22645511 PMC: 3355823. DOI: 10.3389/fendo.2011.00081.

Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.

Sughrue M, Yang I, Kane A, Fang S, Clark A, Aranda D J Neurooncol. 2010; 101(3):463-76.

PMID: 20535527 PMC: 3024496. DOI: 10.1007/s11060-010-0265-y.

Cancer risk following growth hormone use in childhood: implications for current practice.

Ogilvy-Stuart A, Gleeson H Drug Saf. 2004; 27(6):369-82.

PMID: 15144231 DOI: 10.2165/00002018-200427060-00002.